Blog
About

80
views
0
recommends
+1 Recommend
1 collections
    5
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Enabling an Accelerated Development Path for Chlorhexidine Digluconate Gel 7.1% w/w for the Prevention of Omphalitis

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          In 2012, the United Nations (UN), identified chlorhexidine as a Life-saving Commodity and called for the development of a chlorhexidine product suitable for the prevention of omphalitis (umbilical cord infection) in developing countries. In response, GlaxoSmithKline (GSK) set out to develop a chlorhexidine digluconate 7.1% w/w gel, in partnership with Save the Children. The vision was to develop a gel which could pass a stringent regulatory review thereby assuring a safe, effective, and quality product. Review under the European Medicines Agency’s (EMA) Article 58 pathway was pursued, with accelerated assessment granted. The regulatory dossier compiled literature-based evidence for clinical efficacy and safety, supplemented by GSK-generated in-vitro studies and a full CMC data package to support the quality. No new clinical trial data or in vivo non-clinical study data were submitted. A positive opinion from the EMA was received in 2016. The time from the initial UN call to EMA Positive Opinion was 3 years and 7 months.

          Related collections

          Author and article information

          Journal
          BJPharm
          British Journal of Pharmacy
          University of Huddersfield Press
          2058-8356
          11 July 2018
          : 2
          : 2 , Proceedings of the 8 th APS International PharmSci 2017
          : S45-S46
          Affiliations
          GlaxoSmithKline R&D Ltd, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
          Author notes
          *Corresponding author. Tel.: +44 7818 527850 E-mail: elena.deangelis@ 123456gsk.com
          Article
          10.5920/bjpharm.2017.31
          © 2017, L. Immins, N. Jibry, D. Hunt, K. Cheng, P. Chowdhury, C. Patel, S. Wilhelm, E. DeAngelis, P. Williams

          This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/.

          Product

          Comments

          Comment on this article